Treatment of Wilson disease (WD) with medical therapy and degrees of dietary restriction of copper intake is lifelong, but adjustments of treatments and determining their effectiveness require appropriate monitoring. There are two categories of treatment monitoring, monitoring for effectiveness and monitoring for safety. Monitoring requires assessing for changes in health status, including physical exam, blood and urine testing, and imaging. The frequency of monitoring may change according to the clinical status, type of therapy, and phase of treatment. Special attention is given to symptoms related to liver disease, neurologic findings, the appearance of KF rings, psychiatric findings, and quality of life. In addition, monitoring for adherence to treatment links to monitoring for effectiveness as adherence is critical to achieving best patient outcomes. Copper status should be monitored regularly, as some patients may be overtreated, resulting to overlapping symptomatology due to copper excess.
Wilson disease Chelation Copper Zinc Adherence Monitoring
This is a preview of subscription content, log in to check access.
Roberts EA, Schilsky ML, American D, Association for Study of Liver. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089–111.CrossRefPubMedGoogle Scholar
Willis MS, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123(1):125–31.CrossRefPubMedGoogle Scholar
Weiss KH, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11(8):1028-35 e1-2.CrossRefPubMedGoogle Scholar
Karlas T, et al. Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scand J Gastroenterol. 2012;47(11):1353–61.CrossRefPubMedGoogle Scholar
Iorio R, et al. Serum transaminases in children with Wilson’s disease. J Pediatr Gastroenterol Nutr. 2004;39(4):331–6.CrossRefPubMedGoogle Scholar
Dhawan A, et al. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11(4):441–8.CrossRefPubMedGoogle Scholar
Sini M, et al. Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson’s disease. Dig Liver Dis. 2012;44(6):487–91.CrossRefPubMedGoogle Scholar
Sinha S, et al. Sequential MRI changes in Wilson’s disease with de-coppering therapy: a study of 50 patients. Br J Radiol. 2007;80(957):744–9.CrossRefPubMedGoogle Scholar